文献速递外周动脉疾病

基于Medicare关联数据库的慢性肢体威胁性缺血患者腔内优先与旁路优先策略的结局比较

Outcomes of Endovascular-First Versus Bypass-First Approach for Patients With Chronic Limb-Threatening Ischemia Using a Medicare-Linked Database.
PubMed 文献 · Ann Vasc Surg · 2022-04-06

研究利用血管质量倡议-Medicare关联数据库,纳入2010年1月至2016年12月接受肢体血运重建的慢性肢体威胁性缺血患者,比较腔内优先(EVF)与旁路优先(BF)策略的中期结局。EVF组12062例(70%),BF组5166例(30%),中位随访33个月。2年时BF组肢体挽救率、免于再干预率、无截肢生存率和免于全因死亡率均高于EVF组,但校正混杂因素后治疗策略对上述结局未见显著影响。

要点

  • 2年时BF组肢体挽救率86.4% vs EVF组82.1%(P < 0.001)。
  • 校正混杂因素后治疗策略对肢体挽救、再干预、无截肢生存和全因死亡均未见显著影响。
  • EVF组患者年龄更大、合并症更多且组织丢失更常见。

核心结论

  • 本研究是最大的真实世界分析,显示EVF策略在慢性肢体威胁性缺血患者中具有非劣效性,其肢体挽救、耐久性、无截肢生存和全因死亡与BF策略相似。
  • 作者指出,仍需关于血运重建策略在这些复杂患者中作用的1级证据。

研究设计与样本

  • 研究为基于血管质量倡议-Medicare关联数据库的分析,纳入2010年1月至2016年12月接受肢体血运重建的所有患者。
  • 排除有既往血运重建史以及接受杂交或腹股沟以上手术的患者,其余患者分为EVF组和BF组。
  • 主要终点为2年肢体挽救、免于再干预、无截肢生存(AFS)和免于全因死亡(ACM)。

主要发现

  • EVF组12062例(70%),BF组5166例(30%),中位随访33个月(四分位距[IQR]:14-49)。
  • EVF组患者年龄更大、合并症更多且组织丢失更常见。
  • 2年时BF组肢体挽救率86.4% vs EVF组82.1%(P < 0.001),BF组较高。
  • 2年时BF组免于再干预率72% vs EVF组68%(P < 0.001),BF组较高。
  • 2年时BF组AFS 66.9% vs EVF组56.3%(P < 0.001),BF组较高;BF组免于ACM 75.7% vs EVF组66.1%(P < 0.001),BF组较高。

关键数值与推荐

  • 校正潜在混杂因素后,治疗策略对肢体挽救的影响未观察到(aHR 1.03;95%CI 0.93-1.16;P = 0.55)。
  • 校正潜在混杂因素后,治疗策略对再干预的影响未观察到(aHR 0.95;95%CI 0.89-1.019;P = 0.06)。
  • 校正潜在混杂因素后,治疗策略对AFS的影响未观察到(aHR 0.94;95%CI 0.89-1.007;P = 0.08)。
  • 校正潜在混杂因素后,治疗策略对ACM的影响未观察到(aHR 0.93;95%CI 0.87-1.001;P = 0.055)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic limb-threatening ischemia (CLTI) has been increasing in prevalence and remains a significant cause of limb loss and disability and a strong predictor of cardiovascular mortality. Previous studies have demonstrated that endovascular and open repair are similarly effective. These findings led to a significant increase in the adoption of the less-invasive endovascular-first (EVF) approach. However, it remains unknown whether the 2 treatment modalities have similar durability in today's real-world setting. The aim of the present study was to compare the midterm outcomes of the EVF and bypass-first (BF) strategies in patients with CLTI. METHODS: We identified all patients who had undergone limb revascularization from January 2010 to December 2016 in the Vascular Quality Initiative Medicare-linked database. Patients with a history of previous revascularization and those who had undergone hybrid or suprainguinal procedures were excluded from the present study. The remaining patients were divided into 2 groups: EVF and BF. The main end points were 2-year limb salvage, freedom from reintervention, amputation-free survival (AFS), and freedom from all-cause mortality (ACM). RESULTS: The EVF approach was applied to 12,062 patients (70%) and the BF approach to 5,166 patients (30%). The median follow-up was 33 months (interquartile range [IQR]: 14-49). Patients in the EVF group were older and had more comorbidities and tissue loss. At 2 years, the BF group had achieved greater rates of limb salvage (86.4% vs. 82.1%; P < 0.001), freedom from reintervention (72% vs. 68%; P < 0.001), AFS (66.9% vs. 56.3%; P < 0.001), and freedom from ACM (75.7% vs. 66.1%; P < 0.001). After adjusting for potential confounders, an effect of the treatment strategy on limb salvage (adjusted hazard ratio [aHR], 1.03; 95% confidence interval [CI], 0.93-1.16; P = 0.55), reintervention (aHR, 0.95; 95% CI, 0.89-1.019; P = 0.06), AFS (aHR, 0.94; 95% CI, 0.89-1.007; P = 0.08), and ACM (aHR, 0.93; 95% CI, 0.87-1.001; P = 0.055) was not observed. CONCLUSIONS: The present study is the largest real-word analysis showing the noninferiority of the EVF approach in patients with CLTI, with similar limb salvage, durability, AFS, and ACM compared with the BF approach. However, level 1 evidence on the role of the revascularization strategy in these challenging patients is needed.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Mathlouthi A, Elsayed N, Al-Nouri O, et al. Outcomes of Endovascular-First Versus Bypass-First Approach for Patients With Chronic Limb-Threatening Ischemia Using a Medicare-Linked Database. Ann Vasc Surg. 2022. PMID: 35398193. doi:10.1016/j.avsg.2022.03.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。